Evidence map›Paper›PMID 36862114›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2023

A Scalable Platform for Fabricating Biodegradable Microparticles with Pulsatile Drug Release.

Tyler P Graf, Sherry Yue Qiu, Dhruv Varshney, Mei-Li Laracuente, Erin M Euliano, Pujita Munnangi, Brett H Pogostin, Tsvetelina Baryakova, Arnav Garyali, Kevin J McHugh

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Engineered CD4 T cells for in vivo delivery of therapeutic proteins.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tyler P GrafDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0003-4689-9771
Sherry Yue QiuDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0002-5160-6921
Dhruv VarshneyDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0002-3518-6197
Mei-Li LaracuenteDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0001-8220-4207
Erin M EulianoDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0002-9423-8591
Pujita MunnangiDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0002-5001-1205
Brett H PogostinDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0002-1462-4442
Tsvetelina BaryakovaDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.
Arnav GaryaliDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.
Kevin J McHughDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0001-6801-4431

Funding

Training and Dissemination CoreP41EB023833 · NIBIB · UNIV OF MARYLAND, COLLEGE PARK · PI FISHER, JOHN P · 2017 to 2021
$6.2M
Research Supplement to Promote Diversity: Carlos Torres (R03EB031495 Parent Award)R03EB031495 · NIBIB · RICE UNIVERSITY · PI MCHUGH, KEVIN JAMES · 2021 to 2022
$176k
NIBIB NIH HHS P41 EB023833NIBIB NIH HHS R03 EB031495NIH HHS P41 EB023833NIH HHS R03 EB031495
6 · The paper itself

Abstract

Pulsatile drug delivery systems have the potential to improve patient adherence and therapeutic efficacy by providing a sequence of doses in a single injection. Herein, a novel platform, termed Particles Uniformly Liquified and Sealed to Encapsulate Drugs (PULSED) is developed, which enables the high-throughput fabrication of microparticles exhibiting pulsatile release. In PULSED, biodegradable polymeric microstructures with an open cavity are formed using high-resolution 3D printing and soft lithography, filled with drug, and sealed using a contactless heating step in which the polymer flows over the orifice to form a complete shell around a drug-loaded core. Poly(lactic-co-glycolic acid) particles with this structure can rapidly release encapsulated material after delays of 10 ± 1, 15 ± 1, 17 ± 2, or 36 ± 1 days in vivo, depending on polymer molecular weight and end group. The system is even compatible with biologics, releasing over 90% of bevacizumab in its bioactive form after a two-week delay in vitro. The PULSED system is highly versatile, offering compatibility with crystalline and amorphous polymers, easily injectable particle sizes, and compatibility with several newly developed drug loading methods. Together, these results suggest that PULSED is a promising platform for creating long-acting drug formulations that improve patient outcomes due to its simplicity, low cost, and scalability.

Indexed as

Drug Delivery SystemsPolymersDrug CompoundingDrug LiberationHumansParticle SizePolylactic Acid-Polyglycolic Acid CopolymerPolylactic Acid-Polyglycolic Acid CopolymerPolymerscontrolled releasedrug deliveryhigh-throughput formulationmicroparticle fabricationpulsatile release

Identifiers

PMID36862114
PMCPMC10247432

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.